Table 3 Studies on prognostic significance of PIK3CA mutations in several types of cancers

Colon cancer

1212

16

Unfavorable

Adjusted CS HR

[31]

3.51 (1.28–9.62)

743

14.5

Unfavorable

Adjusted OS HR

[25]

3.30 (1.46–7.45)

450

18

Unfavorable

Adjusted CS HR

[29]

2.03 (1.15–3.57)

Rectal cancer

240

7.9

Unfavorable

Adjusted RS HR

[32]

3.4 (1.2–9.2)

Endometrial cancer

1063

16.2

Unfavorable

Not-adjusted RS HR

[33]

2.18 (1.09–4.39)

Breast cancer

687

25.3

favorable

Not-adjusted CS HR

[34]

0.88 (0.58–1.34)

439

32.5

Not significant

Adjusted CS HR

[30]

0.7 (0.4–1.2)

188

28.7

favorable

Adjusted RS HR

[35]

0.42 (0.20–0.92)

Esophageal cancer

406

7.4

Not significant

Adjusted OS HR

[43]

1.072 (0.79–1.44)

219

21

favorable

Adjusted OS HR

[14]

0.35 (0.10–0.90)

Lung cancer

1117

3.4

Not significant

OS log-lank

[44]

P = 0.442

235

3.4

Not significant

OS log-lank

[45]

P = 0.15

Gastric cancer

263

15.9

Not significant

Adjusted OS HR

[27]

1.1 (0.7–1.7)

231

8.7

Not significant

Not-adjusted OS HR

[26]

1.37 (0.68–3.26)

104

7.7

Not significant

OS log-lank

[28]

P = 0.96

208

12

Not significant

Not-adjusted OS HR

This study

0.73 (0.58–2.57)